Results 91 to 100 of about 235,541 (221)

Cytomegalovirus retinitis after an intravitreal dexamethasone implant

, 2020
In this case report an immunocompetent patient developed retinitis after implantation of an intravitreal dexamethasone implant following a primary infection with cytomegalovirus.
Pindbo Vestergaard, Jesper, Thagaard, Mikkel Straarup; id_orcid   +1 more
core   +1 more source

Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies

MedComm, Volume 7, Issue 11, November 2026.
Graphical overview of targeted protein degradation: mechanisms, molecular determinants, delivery strategies, and therapeutic development. This graphical abstract summarizes the major degradation pathways involved in targeted protein degradation, including the ubiquitin–proteasome system, endocytosis–lysosome pathway, and autophagy‐dependent degradation.
Huaijuan Guo, Haishuang Duan, Yang Liu, Kelan Fang, Lujia Xiao, Ling Bai, Xiao Qu, Xuebing Yan, Kun Zhang   +8 more
wiley   +1 more source

Adult‐onset Coats disease: A systematic review and meta‐analysis of imaging biomarkers and targeted therapies

Acta Ophthalmologica, Volume 104, Issue 7, Page e724-e744, November 2026.
Abstract Coats disease diagnosed in adulthood is a rare idiopathic retinal telangiectatic vasculopathy that may differ in phenotype from childhood‐diagnosed cases. This systematic review synthesizes current evidence to characterize its clinical spectrum, imaging features, treatment outcomes and underlying mechanisms, with a focus on immunovascular ...
Catarina Francisco, Nisa Silva, Camiel J. F. Boon   +2 more
wiley   +1 more source

Rhegmatogenous Retinal Detachment with a High Risk of Proliferative Vitreoretinopathy Treated with Episcleral Surgery and an Intravitreal Dexamethasone 0.7-mg Implant

Case Reports in Ophthalmology, 2013
Purpose: To report a case of rhegmatogenous retinal detachment with a high risk of proliferative vitreoretinopathy (PVR) effectively treated with episcleral surgery and an intravitreal dexamethasone 0.7-mg implant.
Michele Reibaldi, Andrea Russo, Antonio Longo, Vincenza Bonfiglio, Maurizio G. Uva, Caterina Gagliano, Mario D. Toro, Teresio Avitabile   +7 more
doaj   +1 more source

Paraneoplastic and Autoimmune Retinopathy Presenting as Isolated Neuro‐Ophthalmic Dysfunction: Two Cases

Clinical and Experimental Neuroimmunology, Volume 17, Issue 4, November 2026.
ABSTRACT Background Paraneoplastic and autoimmune retinopathies can cause progressive visual loss before structural ophthalmic or neurologic findings are diagnostic. Case Presentation A 66‐year‐old woman developed bilateral visual decline and was diagnosed with small‐cell lung cancer‐associated paraneoplastic neuroretinal dysfunction, with persistent ...
Alan B. Dogan, Dean Neutel, Anthony L. Loschner   +2 more
wiley   +1 more source

Switching to an Intravitreal Dexamethasone Implant after Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema: A Review

Life
Among working-age people, diabetic retinopathy and diabetic macular edema are currently considered the main causes of blindness. Nowadays, intravitreal injections are widely acknowledged as a significant milestone in ophthalmology, especially for the ...
Livio Vitiello, Giulio Salerno, Alessia Coppola, Ilaria De Pascale, Giulia Abbinante, Vincenzo Gagliardi, Filippo Lixi, Alfonso Pellegrino, Giuseppe Giannaccare   +8 more
doaj   +1 more source

Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9809-9818, November 2026.
ABSTRACT Context Metabolic syndrome (MetS) is defined by central obesity, insulin resistance, hypertension and dyslipidemia. MetS affects over one‐third of US adults. Beyond its cardiovascular burden, MetS has clinically relevant associations with ocular health and may contribute to a systemic vascular and neuro‐metabolic phenotype involving the retina,
Ron T. Varghese, Ansu A. John
wiley   +1 more source

Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features [PDF]

, 2018
Purpose: To investigate dexamethasone intravitreal implant 0.7 mg (DEX implant) for the treatment of diabetic macular oedema (DME) refractory to anti-vascular endothelial growth factor (anti-VEGF) therapy and evaluate predictive factors.
Katja Hatz, Martin Zinkernagel, Hatz, Katja, Cengiz Tuerksever, Zinkernagel, Martin, Tuerksever, Cengiz, Andreas Ebneter, Pruente, Christian, Christian Pruente, Ebneter, Andreas, Hatz K, Tuerksever C, Pruente C, Ebneter A, Zinkernagel M   +14 more
core   +2 more sources

Intravitreal dexamethasone implant in the crystalline lens

JCRS Online Case Reports, 2014
We report the case of a 58-year-old man who developed macular edema due to superior temporal vein occlusion in his right eye. A dexamethasone implant was inadvertently injected into the crystalline lens. Slitlamp examination revealed the position of the implant. The intralenticular dexamethasone implant was clearly imaged in front of the posterior lens
Aylin Karalezli, Fatma Corak Eroglu
openaire   +1 more source

Treating post-traumatic uveitis by intravitreal injection of 0.7 mg dexamethasone implant (a clinical case)

Российский офтальмологический журнал, 2018
Purpose: to assess the first results of intravitreal injection of an implant of dexamethasone 0.7mg for the treatment of post-traumatic uveitis and prevention of post-traumatic eyeball subatrophy.
I. E. Ioshin, A. S. Gavrilyuk, A. V. Artamonova   +2 more
doaj   +1 more source